arrow
X

Xiaoming Yang

nhc key laboratory of metabolic cardiovascular diseases research
H指数:28
被引数:5,934

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China
2024-03-261
OAAI
Rational design of a 'two-in-one' immunogen DAM drives potent immune response against mpox virus (Jan, 10.1038/s41590-023-01715-7, 2024)

“二合一” 免疫原DAM的合理设计可驱动针对mpox病毒的有效免疫反应 (1月,10.1038/s41590-023-01715-7,2024)

2024-01-150
OA
Rational design of a 'two-in-one' immunogen DAM drives potent immune response against monkeypox virus

“二合一” 免疫原DAM的合理设计可驱动针对猴痘病毒的有效免疫反应

2024-01-0510
PRE
Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection
2023-06-1510
OAAI
Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China
2023-05-013
OAAI
Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6-7 Months: A Phase 4, Randomized, Controlled Trial

肠病毒71疫苗 (Vero细胞) 与三价裂解病毒流感疫苗同时接种6-7个月婴儿的安全性和免疫原性: 一项4期随机对照试验

2023-04-183
OAAI